Medtronic received information through a post market clinical follow-up (pmcf) survey that following use of the cardioblate maps device at an unspecified time the patients experience the following; an extension of bypass and hypotension and the customer stated that these adverse events were directly related to the device and required further medical or surgical intervention.Regarding the extension of bypass, the customer stated that extra time needed to perform the ablation than alone.Regarding the hypotension the customer stated they needed more time to perform the concomitant procedure than otherwise alone and this led to myocardial stunning and longer anesthesia times.
|